Back to search

Article

CBFB mutations predict endocrine therapy benefit in estrogen receptor–positive breast cancer

2026-05-21

Abstract excerpt

<h4>Purpose</h4> Beyond estrogen receptor (ER) positivity, no genomic biomarker reliably identifies ER+ breast cancer patients who derive differential benefit from endocrine therapy (ET). We performed an unbiased genomic screen to discover genes predicting ET response and characterized the top candidate across clinical settings, treatment modalities, and an independent validation cohort. <h4>Experimental Design</...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
d3cc9a6a-2dc7-542c-b9c5-146f06581230
DOI
10.64898/2026.05.18.26353467
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
CBFB mutations predict endocrine therapy benefit in estrogen receptor–positive breast cancerDOI 10.64898/2026.05.18.26353467
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers.Semantic proximity
ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC).Semantic proximity
Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer.Semantic proximity
Impact of clinical targeted sequencing on endocrine responsiveness in estrogen receptor-positive, HER2-negative metastatic breast cancer.Semantic proximity
Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic AnalysisSemantic proximity
Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice.Semantic proximity
Analysis of Paired Primary-Metastatic Hormone-Receptor Positive Breast Tumors (HRPBC) Uncovers Potential Novel Drivers of Hormonal Resistance.Semantic proximity
Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial.Semantic proximity
Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis.Semantic proximity
Molecular profiling of a real-world breast cancer cohort with genetically inferred ancestries reveals actionable tumor biology differences between European ancestry and African ancestry patient populations.Semantic proximity
Genomic landscape of metastatic breast cancers in young adults: a liquid biopsy analysis of women aged 20-40 years.Semantic proximity
The genomic landscape of metastatic breast cancer: Insights from 11,000 tumors.Semantic proximity
Select a neighboring publication to make it the new centre.